IL-15 is known to enhance immunogenicity through promoting the activation of dendritic cells [56] and is upregulated in leukocytes during sepsis [57]; therefore, targeting IL-15 within IEC may be a novel therapeutic option in patients with IBD. This evidence concerns the gene IL15 and inflammatory bowel disease.